Top Page
IRLAB Therapeutics AB Class A
(IRLAB.A)
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
IRLAB Therapeutics AB Class A Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 57.46M | 94.63M | 5.68M | 61.14M | 207.78M |
| Gross Profit | -92.35M | -92.42M | -122.73M | -111.23M | 168.69M |
| EBITDA | -88.03M | -68.07M | -173.32M | -109.13M | 55.79M |
| Net Income | -110.01M | -83.13M | -177.84M | -114.20M | 51.78M |
Balance Sheet | |||||
| Total Assets | 138.21M | 136.21M | 177.12M | 323.56M | 472.45M |
| Cash, Cash Equivalents and Short-Term Investments | 81.86M | 66.92M | 111.31M | 252.78M | 401.90M |
| Total Debt | 29.95M | 60.42M | 27.57M | 3.98M | 6.60M |
| Total Liabilities | 107.49M | 103.58M | 61.36M | 32.72M | 72.97M |
| Stockholders Equity | 30.72M | 32.63M | 115.76M | 290.83M | 399.48M |
Cash Flow | |||||
| Free Cash Flow | -55.22M | -65.79M | -165.14M | -145.99M | 127.93M |
| Operating Cash Flow | -55.22M | -65.59M | -164.85M | -142.61M | 128.64M |
| Investing Cash Flow | 0.00 | -199.00K | -293.00K | -3.38M | -708.00K |
| Financing Cash Flow | 73.41M | 21.40M | 23.68M | -3.13M | -3.04M |
IRLAB Therapeutics AB Class A Technical Analysis
IRLAB Therapeutics AB Class A Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr195.09M | -9.08 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr193.96M | -2.92 | -51.35% | ― | ― | -34.02% | |
49 Neutral | kr218.76M | -4.03 | ― | ― | -7.68% | 17.93% | |
49 Neutral | kr289.76M | -13.67 | -48.30% | ― | ― | 52.96% | |
45 Neutral | kr126.53M | -1.66 | -1291.15% | ― | ― | 28.54% | |
43 Neutral | kr138.28M | -1.72 | -199.86% | ― | 69.03% | 23.10% |
IRLAB Therapeutics AB Class A Corporate Events
IRLAB Therapeutics AB, a Swedish biotech specializing in innovative Parkinson’s disease therapies, is advancing a diversified pipeline that spans late-stage candidates for levodopa-induced dyskinesias and fall reduction, as well as earlier-stage projects targeting apathy and other neurodegenerative symptoms. The company leverages a proprietary systems biology platform to support its clinical and preclinical programs and strengthen its positioning in neurology-focused drug development.
IRLAB announced it will present at Life Science Day in Gothenburg on March 4, 2026, where CFO Gustaf Albèrt will give an update followed by a Q&A session. Participation in this investor-oriented event, organized to showcase life science companies, provides IRLAB with a platform to highlight its pipeline progress, increase visibility among investors and industry stakeholders, and potentially support future financing and partnership opportunities.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics has dosed the first patient in its Phase Ib LIFT-PD trial of IRL757, a potential treatment for apathy in Parkinson’s disease, triggering a USD 3 million milestone payment from its development partner, the McQuade Center for Strategic Research and Development, an Otsuka subsidiary. The fully funded study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland and Spain, building on earlier Phase I data that showed IRL757 was well tolerated and well absorbed in healthy adults.
The progress with IRL757 strengthens IRLAB’s financial position and advances a candidate that could become the first approved therapy for apathy, which affects millions of people with Parkinson’s and Alzheimer’s disease in major global markets. Positive preclinical data indicating improved motivation and a mechanism aimed at restoring disrupted cortical-subcortical nerve signaling underpin the program, supporting IRLAB’s positioning in a high unmet-need segment of neurodegenerative disease treatment.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics reported full-year 2025 results showing net sales of SEK 57.5 million, a widened operating loss of SEK 93.4 million and year-end cash of SEK 81.9 million, while maintaining an average of 31 employees and seeing its share price decline to SEK 1.97. The company advanced its pipeline with a Phase Ib study of IRL757 in Parkinson’s disease and apathy now underway in Europe funded by MSRD, received strong backing from international experts for its drug pirepemat, confirmed attractive market potential for mesdopetam in levodopa-induced dyskinesia, and initiated a collaboration with Biomia to apply its ISP platform to new CNS compounds, developments that strengthen its clinical strategy despite ongoing losses.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics has received unanimous backing from its scientific advisory board to proceed with development of its Parkinson’s candidate pirepemat, after experts judged the pharmacological rationale sound and the reduction in falls seen in a Phase IIb trial to be clinically meaningful. The board, comprising leading neurologists from North America and Europe, emphasized that falls remain a significant unmet need with no approved pharmaceutical treatments, and concluded that pirepemat’s observed effect and mechanism of action justify further clinical studies, reinforcing IRLAB’s strategic focus on improving quality of life for Parkinson’s patients.
IRLAB’s leadership said the feedback confirms pirepemat’s potential to fill a critical treatment gap for patients prone to falls, underscoring the candidate’s promise to deliver meaningful therapeutic benefits. The endorsement strengthens the company’s position in the Parkinson’s pipeline landscape and could support future trial planning, partnerships, and investor confidence as it advances pirepemat toward late-stage development.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB, a Nasdaq Stockholm-listed biopharmaceutical developer of novel Parkinson’s disease treatments, will publish its year-end 2025 report on February 25, 2026, at 07:00 CET. The Gothenburg-based company, led by CEO Kristina Torfgård, continues to advance a pipeline spanning late-stage clinical assets and early-stage candidates targeting motor and neuropsychiatric complications in Parkinson’s and other neurodegenerative disorders.
On the same day at 10:00 CET, IRLAB’s management team will present the year-end results via a digital webcast in Swedish, followed by a Q&A session for investors and other stakeholders. The live-streamed presentation, along with the interim report and a recorded version of the webcast, will be made available on the company’s website and YouTube channel, enhancing transparency and accessibility around its financial and R&D progress.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics has entered a collaboration with Danish biotech firm Biomia ApS to apply IRLAB’s Integrative Screening Process (ISP) platform to Biomia’s small-molecule drug candidates targeting undisclosed central nervous system indications. Under the agreement, IRLAB will use its ML/AI-supported ISP technology to provide phenotypic characterization, indication prediction, and differentiation versus existing treatments for Biomia’s novel chemistries, while Biomia supplies the compounds and funds the studies, reinforcing IRLAB’s position as a specialist CNS discovery partner and potentially expanding the commercial reach and validation of its ISP platform within the broader biotech ecosystem.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics has obtained regulatory and ethical approval to initiate a Phase Ib clinical study of its drug candidate IRL757 in Parkinson’s disease patients suffering from apathy, a disabling symptom for which no approved treatments currently exist. The fully MSRD-funded trial will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland and Spain, building on earlier Phase I studies in healthy adults that demonstrated good absorption, systemic exposure and no serious adverse events. IRL757, which has shown positive effects on cognitive function and motivation in preclinical models through its proposed ability to restore disrupted cortical–subcortical nerve signalling, is being advanced under a collaboration with Otsuka group’s McQuade Center and could emerge as the first approved therapy for apathy in Parkinson’s and other neurodegenerative diseases, targeting a large, currently underserved patient population in the US, Europe and other major markets.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB announced that the European Patent Office intends to grant a new patent for mesdopetam, covering various salt forms of the drug candidate. This patent enhances the intellectual property portfolio of mesdopetam, supporting its market exclusivity and commercialization efforts, which could significantly impact the company’s operations and industry positioning by extending market exclusivity into the mid-2040s across major markets.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.